USP <61> and <62> Microbial Limits Testing: What Supplement Brands Keep Getting Wrong

Every year, FDA Form 483 observations tell the same story. Among the thousands of inspections conducted at dietary supplement manufacturing facilities, failures in laboratory control procedures rank consistently among the top five citation categories — and a disproportionate share trace back to a deceptively simple question: was USP <61> and <62> actually run correctly?

Not “did you get a passing COA.” That’s a different question entirely. The method — the inoculation conditions, the suitability requirements, the acceptance criteria appropriate for your product category — is where most gaps hide. And they hide well, because a passing result looks identical on paper whether the test was done right or done fast.

What USP <61> and <62> Are (and Aren’t)

USP <61>, Microbiological Examination of Nonsterile Products: Microbial Enumeration Tests, is a quantitative method. It gives you two numbers: Total Aerobic Microbial Count (TAMC) and Total Yeast and Mold Count (TYMC), both reported in CFU per gram or per mL. TAMC incubates on casein soya bean digest agar at 30–35°C for 5 days; TYMC uses Sabouraud dextrose agar at 20–25°C for 5 days.

USP <62>, Microbiological Examination of Nonsterile Products: Tests for Specified Microorganisms, is qualitative. It answers presence/absence questions about specific pathogens: Salmonella spp., Escherichia coli, bile-tolerant gram-negative bacteria, Staphylococcus aureus, Pseudomonas aeruginosa, and Candida albicans, among others, depending on product type and applicable monograph.

Here’s what these chapters are not: they don’t set your acceptance criteria. That’s USP <1111> — Acceptance Criteria for Pharmaceutical Preparations and Substances for Pharmaceutical Use — which provides guidance by product category. For non-aqueous oral preparations (capsules, tablets, powders), the <1111> guidance is ≤10³ CFU/g for TAMC and ≤10² CFU/g for TYMC. For aqueous oral preparations, those limits tighten significantly — to ≤10² and ≤10¹ respectively. Under 21 CFR Part 111, supplement manufacturers are required to establish their own written microbial specifications, but those specs must reflect real product risk, and USP <1111> is the reference FDA auditors use when evaluating whether your limits are scientifically defensible.

This distinction matters more than it sounds. We routinely see COAs where the acceptance criterion is cited without a source, or where the wrong category limit is applied altogether. A TAMC result of 500 CFU/g looks fine for a dry encapsulated powder and fails for a botanical liquid extract. Same number, different product, different compliance status.

Method Suitability: The Test Before the Test

The part of USP <61> most consistently shortchanged is method suitability — what earlier editions of the chapter called method validation. Before you can trust enumeration results, you have to demonstrate that the product matrix isn’t suppressing microbial growth inside the test system itself.

This matters enormously for botanical supplements. Ingredients like oregano extract, berberine, thyme, garlic, and tea tree oil carry well-documented antimicrobial activity. If your lab spikes a sample with Staphylococcus aureus ATCC 6538 and recovers fewer than 50% of the inoculated colony count, the method has a suitability failure. The product is actively killing the test organisms, which means your TAMC result is artificially suppressed — and cannot be taken at face value.

USP <61> requires method suitability testing using five reference organisms: S. aureus ATCC 6538, Bacillus subtilis ATCC 6633, Pseudomonas aeruginosa ATCC 9027, Candida albicans ATCC 10231, and Aspergillus brasiliensis ATCC 16404. Recovery must fall between 50% and 200% of the expected inoculum count. If direct inoculation fails that range, the lab must neutralize the antimicrobial interference, increase the dilution factor, or switch to membrane filtration — and then re-demonstrate suitability using the modified procedure.

Method suitability is also not a one-time event. It should be repeated when a product formulation changes, when a new ingredient is introduced, or when you change contract manufacturers. A suitability study completed on your original formula may be entirely invalid for a version that added 50 mg of oregano extract. At Qalitex, our ISO 17025–accredited microbiology team runs product-specific method suitability for every new product submission and flags any reformulation that involves ingredients with known antimicrobial activity. It adds roughly 5 to 7 business days to the initial testing cycle — but the alternative is reporting numbers that have no reliable relationship to what’s actually in the product.

Four Places COAs Commonly Mislead

The certificate of analysis is only as meaningful as the method behind it. A few patterns we see more often than we should:

Limits cited without a source. A COA that reads “TAMC: 850 CFU/g — Pass (<10,000 CFU/g)” is citing a 10⁴ limit. That may be defensible for a non-aqueous oral supplement — but only if your written specification documents that limit and its scientific basis. Under 21 CFR Part 111, finished product testing must demonstrate conformance to written specifications. If the limit on the COA doesn’t trace back to an approved product spec with a cited reference, you have a documentation gap even if the result itself is scientifically reasonable.

Absence/presence results without a specified test portion. USP <62> tests are performed on a defined quantity — typically 1 g or 10 g, depending on the organism and the applicable monograph. A Salmonella “Not Detected” result on 1 g is a fundamentally different statement than “Not Detected” on a 25 g test portion, which is the standard for most food applications under ISO 6579 and the FDA Bacteriological Analytical Manual. Supplement COAs don’t always document the test portion, and that gap can matter when reconciling results against retailer specs or export market requirements.

No documentation of growth promotion testing. Every lot of microbiological media used in USP <61> and <62> testing must pass growth promotion testing before use. This step confirms that the media can actually support the target organisms — a compromised lot of agar can suppress colony growth just as effectively as an antimicrobial ingredient can. Any accredited lab doing this work should be able to provide media lot traceability and growth promotion results on request. If they can’t, that’s worth taking seriously.

Suitability data applied across unrelated formulations. Some labs run method suitability once on a “representative matrix” and apply it to all products in the same broad category. That approach doesn’t hold for botanically complex products. If suitability was demonstrated on a plain whey protein and your product is a combination garlic–black seed oil capsule, that data doesn’t transfer. Ask explicitly: was suitability tested on this specific formula? The answer should be unambiguous.

For EU market entry and European regulatory compliance, Care Europe provides expert consulting from Paris.

What to Actually Do With This

If you’re a supplement brand reviewing third-party microbial results, three questions are worth asking before any batch is released to market.

First: can the lab produce method suitability data specific to your product formula — not a generic report for the matrix type, but suitability data for the actual ingredients in this product?

Second: does the acceptance limit on the COA match the limit in your written specification, and does that specification document the scientific basis for the limit, citing USP <1111> or the applicable dietary supplement monograph?

Third: for <62> absence/presence results, what was the test portion size — and does it meet what your retail customers, distributors, or import markets actually require?

These aren’t difficult questions. Any ISO 17025–accredited microbiology lab doing this work properly should have specific, immediate answers to all three. Vague responses — “we follow industry standards” or “our methods are fully validated” — are a prompt to ask more precisely, not a satisfactory answer.

Microbial testing in dietary supplements is genuinely well-defined work. The methods are published. The organisms are specified. The incubation conditions are explicit. What makes it complicated isn’t the science — it’s the gap between “we ran the test” and “we ran the test in a way that actually tells you something about product safety.” That gap is worth identifying and closing before your product reaches a consumer’s hands.